This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

Let's collaborate Boehringer Ingelheim

WCLC - Nowak Presentation

Nintedanib + pemetrexed/cisplatin in malignant pleural mesothelioma: Phase II biomarker data from the LUME-Meso study

Nowak K, Grosso F, Steele N, Novello S, Popat S, Greillier L, John T, Leighl N, Reck M, Pavlakis N, Sørensen J, Planchard D, Ceresoli G, Hughes B, Mazières J, Socinski M, Salnikov A, Kitzing T, Braunger J, Pietzko K, Scagliotti G

RELATED ARTICLES

Learn more about the science behind this presentation in the papers and other materials below

 

Nintedanib plus pemetrexed/cisplatin in patients with malignant pleural mesothelioma: Phase II results from the randomized, placebo-controlled LUME-Meso trial

Grosso F et al. JCO 2017; DOI: 10.1200/JCO.2017.72.9012

LUME-Meso: design and rationale of the Phase III part of a placebo-controlled study of nintedanib and pemetrexed/cisplatin followed by maintenance nintedanib in patients with unresectable malignant pleural mesothelioma

Scagliotti G et al. CLC 2017; DOI: 10.1016/j.cllc.2017.03.010

Related information

About nintedanib

A detailed look at nintedanib’s mechanism of action and the role of angiogenesis in cancer

Oncology Resources

Find a detailed bibliography of clinical data and case studies, and a library of downloadable resources containing up-to-date background information on key therapy areas in oncology

WCLC 2017

Find information on afatinib and nintedanib's clinical data and Boehringer Ingelheim's activities at WCLC 2017
Back to top

Nintedanib is being investigated in malignant pleural mesothelioma (MPM) and is not approved for this use. The efficacy and safety of nintedanib in MPM have not been established.